UBS analyst Joseph Parkhill maintains RXO (NYSE:RXO) with a Neutral and raises the price target from $22 to $31.
UBS Maintains Neutral on RXO, Raises Price Target to $31
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.